Form 4: Enanta Pharmaceuticals Chief Scientific Officer Acquires 87,000 Stock Options
SEC Form 4 Filing
Enanta Pharmaceuticals' Chief Scientific Officer, Or Yat Sun, was granted 87,000 stock options on November 27, 2024, exercisable over four years.
Summary
- On November 27, 2024, Or Yat Sun, the Chief Scientific Officer of Enanta Pharmaceuticals, was granted 87,000 stock options.
- These options have an exercise price of $8.83 per share.
- The options will vest quarterly over four years from the grant date, subject to continued employment.
- The options expire on November 27, 2034.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management with shareholder interests. There are no negative implications or surprises.
Positives
- The grant of stock options to the Chief Scientific Officer aligns his interests with the long-term success of the company.
- The vesting schedule encourages continued employment and contribution from the executive.
Industry Context
Stock option grants are a common form of executive compensation in the pharmaceutical industry, aligning management's interests with shareholder value and incentivizing long-term performance.
Comparison to Industry Standards
- Stock option grants are a standard practice for incentivizing executives in the biotechnology and pharmaceutical industries.
- The vesting schedule of four years is typical for such grants, ensuring long-term commitment from the executive.
- The exercise price of $8.83 is a specific value for this grant and would need to be compared to other similar grants to determine if it is in line with industry standards.
Stakeholder Impact
- The stock option grant may positively impact shareholder value by incentivizing the Chief Scientific Officer to drive company success.
- The grant does not have any immediate impact on employees, customers, suppliers or creditors.
Key Dates
| Date | Description |
|---|---|
| 11/27/2024 | Date of the stock option grant and the earliest transaction date. |
| 11/27/2034 | Expiration date of the stock options. |
Keywords
stock options, Enanta Pharmaceuticals, Chief Scientific Officer, Or Yat Sun, executive compensation, vesting, equity
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.